{"filings":[{"id":2577280,"accession_number":"0000939767-26-000104","cik":939767,"company_name":"EXELIXIS, INC.","ticker":"EXEL","form_type":"8-K","filed_at":"2026-08-31T20:18:04+00:00","items":["8.01"],"status":"ready","headline":"Federal Circuit affirms Exelixis patents; generic competitor blocked until Jan 15, 2030","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Court of Appeals affirmed validity of U.S. Patent Nos. 11,091,439, 11,091,440, 11,098,015.","FDA approval of MSN's ANDA effective no earlier than Jan 15, 2030, subject to appeals and exclusivity.","MSN's appeal on patent 11,298,349 dismissed as moot; that ruling vacated.","Separate litigation on patent 12,128,039 (expires Feb 2032) with trial set for Nov 2026.","Outcome protects Exelixis from generic competition until at least 2030."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":12575294138.486397,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":"2026-08-31","daily_digest_url":"/daily/2026-08-31","daily_digest_rank":9},{"id":2078965,"accession_number":"0000939767-26-000096","cik":939767,"company_name":"EXELIXIS, INC.","ticker":"EXEL","form_type":"8-K","filed_at":"2026-08-05T20:09:37+00:00","items":["2.02","9.01"],"status":"ready","headline":"Exelixis Q2 2026 revenue $628.7M, GAAP EPS $0.82, non-GAAP EPS $0.91","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $628.7M, up 11% YoY; cabozantinib U.S. net product revenues $573.0M.","GAAP net income $212.1M ($0.82 diluted EPS) vs $184.8M ($0.65) in Q2 2025.","Non-GAAP net income $237.1M ($0.91 diluted EPS) vs $212.6M ($0.75) YoY.","R&D expenses $212.0M, SG&A $147.6M; both up YoY on clinical and marketing costs.","Zanzalintinib potential launch in metastatic colorectal cancer pending regulatory approval later 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12575294138.486397,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":746559,"accession_number":"0000939767-26-000074","cik":939767,"company_name":"EXELIXIS, INC.","ticker":"EXEL","form_type":"8-K","filed_at":"2026-05-29T20:05:57+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Exelixis shareholders approve 2017 equity plan amendment, adding 2M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved amendment to 2017 Plan, adding 2,000,000 shares to the share reserve.","Full Value Awards granted on or after May 26, 2026, will count as 1 share per share issued (previously 2 for 1).","All 11 director nominees elected; Ernst & Young ratified as auditor; say-on-pay approved.","Amended plan effective immediately upon stockholder approval at May 26, 2026 annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":12575294138.486397,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99924,"accession_number":"0000939767-26-000058","cik":939767,"company_name":"EXELIXIS, INC.","ticker":"EXEL","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Exelixis Q1 revenue $610.8M, GAAP EPS $0.79; announces $750M buyback","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $610.8M (+10% YoY); cabozantinib U.S. net product revenue $555.0M.","GAAP diluted EPS $0.79 (vs. $0.55 in Q1 2025); non-GAAP diluted EPS $0.87.","Board authorized new $750M stock repurchase program through Dec 31, 2027.","Zanzalintinib NDA accepted for colorectal cancer; PDUFA target Dec 3, 2026.","Company plans to complete current $750M buyback this month."],"consensus_eps_estimate":null,"consensus_eps_actual":0.79,"consensus_revenue_estimate":null,"consensus_revenue_actual":610812000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12575294138.486397,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116221,"accession_number":"0000939767-26-000019","cik":939767,"company_name":"EXELIXIS, INC.","ticker":"EXEL","form_type":"8-K","filed_at":"2026-02-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Exelixis Q4 revenue $599M, diluted EPS $0.88; cabozantinib franchise up 17% in FY2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 total revenue $598.7M vs $566.8M YoY; GAAP diluted EPS $0.88 vs $0.48.","FY2025 net product revenue $2.123B, up from $1.809B, driven by cabozantinib volume growth.","GAAP net income $782.6M in FY2025 ($2.78 diluted EPS); non-GAAP $869.5M ($3.08 diluted EPS).","R&D expenses fell to $825M (down 9.4% YoY); SG&A rose 5.4% to $518.7M.","NDA for zanzalintinib in mCRC accepted; STELLAR-303/304 readouts and trials expected in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":2.78,"consensus_revenue_estimate":null,"consensus_revenue_actual":2320126000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12575294138.486397,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116220,"accession_number":"0000939767-26-000003","cik":939767,"company_name":"EXELIXIS, INC.","ticker":"EXEL","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Exelixis releases preliminary FY2025 results, FY2026 guidance; audit ongoing","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Preliminary unaudited FY2025 results announced; specific financial figures not included in filing.","Financial guidance for FY2026 provided; details not disclosed in the exhibit text available.","Business update delivered; audited FY2025 results to be reported on February 10, 2026.","Audit of FY2025 financial statements is ongoing and may change preliminary information."],"consensus_eps_estimate":null,"consensus_eps_actual":2.78,"consensus_revenue_estimate":null,"consensus_revenue_actual":2320126000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":12575294138.486397,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132675,"accession_number":"0000939767-25-000133","cik":939767,"company_name":"EXELIXIS, INC.","ticker":"EXEL","form_type":"8-K","filed_at":"2025-11-07T23:59:59+00:00","items":["5.02","8.01"],"status":"ready","headline":"Exelixis GC Jeff Hessekiel resigns; Brenda Hefti promoted to succeed him","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jeffrey Hessekiel, EVP & General Counsel, resigns effective Nov 2025; ceases role Nov 7.","Resignation not due to any disagreement with the company.","Brenda Hefti, SVP IP & Licensing, promoted to General Counsel effective Nov 7, 2025.","Hefti joined in 2013, became Head of IP in 2014, and SVP since 2020; reports to CEO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":12575294138.486397,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132674,"accession_number":"0000939767-25-000127","cik":939767,"company_name":"EXELIXIS, INC.","ticker":"EXEL","form_type":"8-K","filed_at":"2025-11-04T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Exelixis Q3 revenues $597.8M, EPS $0.69; announces $750M stock buyback by 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $597.8M (+10.8% YoY); cabozantinib US net product rev $542.9M (+13.5% YoY).","GAAP diluted EPS $0.69 (vs $0.40); Non-GAAP diluted EPS $0.78 (vs $0.47).","Board authorized $750M stock repurchase program through Dec 31, 2026.","Restructuring charges $19.8M related to corporate reorganization; plan to close King of Prussia office.","Zanzalintinib NDA submission planned before year-end based on positive STELLAR-303 colorectal cancer data."],"consensus_eps_estimate":null,"consensus_eps_actual":1.9,"consensus_revenue_estimate":null,"consensus_revenue_actual":1721463000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":12575294138.486397,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149195,"accession_number":"0000939767-25-000115","cik":939767,"company_name":"EXELIXIS, INC.","ticker":"EXEL","form_type":"8-K","filed_at":"2025-08-29T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Exelixis appoints Dana Aftab as EVP R&D; Amy Peterson departs as CMO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dana Aftab, Ph.D., promoted to EVP of R&D effective August 29, 2025; previously EVP Discovery & CSO.","Amy C. Peterson, M.D., concluded service as EVP Product Development and CMO on same date.","Dr. Peterson eligible for severance under Exelixis's Change in Control and Severance Benefit Plan.","No other officer changes disclosed; Dr. Aftab's compensation terms unchanged from prior proxy filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12575294138.486397,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149194,"accession_number":"0000939767-25-000111","cik":939767,"company_name":"EXELIXIS, INC.","ticker":"EXEL","form_type":"8-K","filed_at":"2025-07-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Exelixis Q2 2025: total rev $568M, GAAP EPS $0.65; CABOMETYX NET launch, positive STELLAR-303","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $568.3M; product revenues $520.0M (+19% YoY); collaboration rev $48.2M (down $151M due to prior-year Ipsen milestone).","GAAP net income $184.8M ($0.65 diluted EPS); non-GAAP net income $212.6M ($0.75 diluted EPS).","CABOMETYX launch in advanced NET capturing leading share, representing ~4% of Q2 CABOMETYX business.","Positive topline results from zanzalintinib STELLAR-303 study in colorectal cancer; plan to file for approval.","Early pipeline advancing: phase 1 trials for XL309, XB010, XB628; XB371 entering clinic."],"consensus_eps_estimate":null,"consensus_eps_actual":1.2,"consensus_revenue_estimate":null,"consensus_revenue_actual":1123708000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":12575294138.486397,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168207,"accession_number":"0000939767-25-000097","cik":939767,"company_name":"EXELIXIS, INC.","ticker":"EXEL","form_type":"8-K","filed_at":"2025-06-02T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Exelixis shareholders elect all 11 directors, ratify auditor, approve say-on-pay at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All 11 director nominees elected with strong majorities; broker non-votes of ~24M shares.","Ernst & Young ratified as auditor for FY ending Jan 2, 2026: 243M for, 6.4M against.","Advisory say-on-pay proposal approved: 218.9M for, 6.8M against, 24M broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":12575294138.486397,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168206,"accession_number":"0000939767-25-000074","cik":939767,"company_name":"EXELIXIS, INC.","ticker":"EXEL","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Exelixis Q1 2025: Revenue $555.4M, GAAP EPS $0.55; raises FY2025 guidance by $100M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $555.4M (up 31% YoY); Cabozantinib U.S. net product revenues $513.3M (up 36% YoY).","GAAP diluted EPS $0.55 vs $0.12 in Q1 2024; Non-GAAP diluted EPS $0.62 vs $0.17.","Increasing 2025 full year net product revenues and total revenues guidance by $100M.","CABOMETYX launched in advanced NET after March FDA approval; initial reception positive.","Pipeline milestones: zanzalintinib pivotal readouts in CRC, nccRCC expected H2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":0.55,"consensus_revenue_estimate":null,"consensus_revenue_actual":555447000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":12575294138.486397,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185404,"accession_number":"0000939767-25-000049","cik":939767,"company_name":"EXELIXIS, INC.","ticker":"EXEL","form_type":"8-K","filed_at":"2025-03-31T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Exelixis approves special PSU awards for all employees with $60 stock price performance goal","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Michael Morrissey receives 589,719 shares of PSU; other NEOs receive between 132,819 and 170,009 shares.","Performance condition requires VWAP of $60 or more for 90 consecutive days within 5-year period.","Full vesting requires employment through fifth anniversary; forfeiture if stock price goal not met.","Program designed to align all employee interests with shareholder value creation over five years."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":12575294138.486397,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185403,"accession_number":"0000939767-25-000032","cik":939767,"company_name":"EXELIXIS, INC.","ticker":"EXEL","form_type":"8-K","filed_at":"2025-02-21T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Exelixis board authorizes additional $500M stock repurchase program","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["New $500M authorization to be completed by Dec 31, 2025; current $500M program expected to finish in Q2 2025.","Fourth buyback program since March 2023; cumulative shareholder returns exceed $1.2B as of FY2024 end.","Repurchases may be executed via open market, block trades, ASR, or exchange transactions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12575294138.486397,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185402,"accession_number":"0000939767-25-000017","cik":939767,"company_name":"EXELIXIS, INC.","ticker":"EXEL","form_type":"8-K","filed_at":"2025-02-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Exelixis Q4 2024 rev $567M, GAAP EPS $0.48; FY2024 rev $2.17B, EPS $1.76","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $566.8M for Q4 2024, up 18% YoY; FY2024 total rev $2.17B, up 18% YoY.","GAAP diluted EPS $0.48 (Q4 2024) vs $0.27 (Q4 2023); FY2024 $1.76 vs $0.65.","Non-GAAP diluted EPS $0.55 (Q4 2024) vs $0.33; FY2024 $2.00 vs $0.90.","Cabozantinib franchise U.S. net product revenues $515M (Q4), $1.81B (FY2024), up from $429M and $1.63B."],"consensus_eps_estimate":null,"consensus_eps_actual":1.76,"consensus_revenue_estimate":null,"consensus_revenue_actual":2168701000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":12575294138.486397,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185401,"accession_number":"0000939767-25-000004","cik":939767,"company_name":"EXELIXIS, INC.","ticker":"EXEL","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Exelixis announces preliminary FY2025 results and FY2026 guidance; audit pending","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Preliminary unaudited results for fiscal year ended Jan 3, 2025 provided in press release.","Financial guidance for fiscal year ending Jan 2, 2026 also included.","Audited financial results scheduled for release on February 11, 2025.","Business update delivered along with financial disclosures."],"consensus_eps_estimate":null,"consensus_eps_actual":1.76,"consensus_revenue_estimate":null,"consensus_revenue_actual":2168701000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":12575294138.486397,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201988,"accession_number":"0000939767-24-000149","cik":939767,"company_name":"EXELIXIS, INC.","ticker":"EXEL","form_type":"8-K","filed_at":"2024-10-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Exelixis Q3 revenue $539.5M, EPS $0.40; raises FY 2024 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 net product revenue $478.1M (cabozantinib franchise) vs $426.5M YoY, +12%.","GAAP diluted EPS $0.40, non-GAAP diluted EPS $0.47; prior year $0.00 and $0.10.","Raises 2024 total revenue and net product revenue guidance on strong commercial performance.","Favorable U.S. District Court ruling on cabozantinib patent litigation received.","New collaboration with Merck adds two phase 3 trials for zanzalintinib in renal cell carcinoma."],"consensus_eps_estimate":null,"consensus_eps_actual":1.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":1601946000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.78,"calibrated_materiality_score":0.78,"market_cap_usd":12575294138.486397,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201987,"accession_number":"0000939767-24-000140","cik":939767,"company_name":"EXELIXIS, INC.","ticker":"EXEL","form_type":"8-K","filed_at":"2024-10-15T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Exelixis wins patent case against MSN; generic launch blocked until Jan 2030","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Delaware court rejected MSN's invalidity challenges to three cabozantinib patents (11,091,439, 11,091,440, 11,098,015), all expiring Jan 15, 2030.","Court found MSN's ANDA product infringes those three patents; separate patent 11,298,349 (exp 2032) was not infringed.","Final judgment due Oct 22; FDA cannot approve MSN's generic before Jan 15, 2030 at the earliest.","Ruling protects Exelixis' cabozantinib franchise from generic entry for over five additional years."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":12575294138.486397,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201986,"accession_number":"0000939767-24-000138","cik":939767,"company_name":"EXELIXIS, INC.","ticker":"EXEL","form_type":"8-K","filed_at":"2024-10-15T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Exelixis enters clinical collaboration with Merck for zanzalintinib combo trials in HNSCC and RCC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Collaboration covers zanzalintinib + KEYTRUDA in phase 3 HNSCC trial (STELLAR-305) and zanzalintinib + WELIREG in RCC phase 1/2 and two phase 3 trials.","Merck supplies KEYTRUDA and sponsors one RCC phase 3; Exelixis co-funds phase 1/2 and other phase 3, supplies zanzalintinib and cabozantinib.","Exelixis retains all global commercial and marketing rights to zanzalintinib."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12575294138.486397,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218032,"accession_number":"0000939767-24-000116","cik":939767,"company_name":"EXELIXIS, INC.","ticker":"EXEL","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Exelixis Q2 revenue $637M, GAAP EPS $0.77; $500M buyback, FDA accepts cabozantinib sNDA","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $637.2M vs $469.8M YoY; cabozantinib U.S. net product revenues $437.6M.","GAAP diluted EPS $0.77 vs $0.25 YoY; non-GAAP diluted EPS $0.84 vs $0.31.","FDA accepted sNDA for cabozantinib in advanced NET; target action date April 3, 2025.","Earned $150M milestone from Ipsen; completed $450M buyback; new $500M buyback authorized through 2025.","Discontinued XB002 development; plans to initiate phase 3 for zanzalintinib in NET."],"consensus_eps_estimate":null,"consensus_eps_actual":0.88,"consensus_revenue_estimate":null,"consensus_revenue_actual":1062404000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":12575294138.486397,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237979,"accession_number":"0000939767-24-000081","cik":939767,"company_name":"EXELIXIS, INC.","ticker":"EXEL","form_type":"8-K","filed_at":"2024-06-03T23:59:59+00:00","items":["5.02","5.07"],"status":"ready","headline":"Exelixis stockholders approve ESPP share increase and elect directors at 2024 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Approved amendment to 2000 Employee Stock Purchase Plan, increasing authorized shares by 6 million.","Elected 11 directors to serve until 2025 annual meeting; all nominees received majority support.","Ratified Ernst & Young as independent auditor for fiscal year ending Jan 3, 2025; 254.6M votes for.","Advisory Say on Pay proposal approved with 226.7M votes for, 9.8M against.","Broker non-votes of 26.5M shares across director elections and other proposals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":12575294138.486397,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237978,"accession_number":"0000939767-24-000074","cik":939767,"company_name":"EXELIXIS, INC.","ticker":"EXEL","form_type":"8-K","filed_at":"2024-05-20T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Exelixis settles CABOMETYX patent litigation; Cipla generic launch from Jan 1, 2031","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Settlement with Cipla resolves two Hatch-Waxman patent suits over CABOMETYX (cabozantinib).","Cipla receives license to market generic CABOMETYX in US starting January 1, 2031, if FDA approved.","All ongoing Delaware district court litigation will be dismissed pending FTC review.","Agreement confidential and subject to review by FTC and DOJ."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":12575294138.486397,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237977,"accession_number":"0000939767-24-000062","cik":939767,"company_name":"EXELIXIS, INC.","ticker":"EXEL","form_type":"8-K","filed_at":"2024-05-10T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Exelixis sues Cipla over generic Cabometyx patents covering 20mg, 40mg strengths","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Cipla amended its ANDA to seek approval for 20mg and 40mg generic cabozantinib, adding Paragraph IV certifications.","Exelixis filed a patent infringement complaint on May 9, 2024 in Delaware federal court.","Five patents asserted: U.S. Patent Nos. 8,877,776, 11,091,439, 11,091,440, 11,098,015, 11,298,349.","Exelixis seeks order that FDA approval be no earlier than the latest patent expiration on February 10, 2032."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12575294138.486397,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237976,"accession_number":"0000939767-24-000054","cik":939767,"company_name":"EXELIXIS, INC.","ticker":"EXEL","form_type":"8-K","filed_at":"2024-04-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Exelixis Q1: revenue $425M, GAAP EPS $0.12, non-GAAP $0.17, restructuring $32.8M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $425.2M, up 4% YoY from $408.8M; cabozantinib U.S. net product revenues $378.5M, up from $363.4M.","GAAP net income $37.3M ($0.12 diluted EPS); non-GAAP net income $52.0M ($0.17 diluted EPS) vs $52.8M ($0.16) in Q1 2023.","Recorded $32.8M restructuring expenses (severance, asset impairment, contract termination) from January 2024 restructuring.","Pipeline: three ongoing pivotal trials for zanzalintinib; phase 1 studies for XB002 (ADC) and XL309 (USP1 inhibitor); up to three IND filings expected in 2024.","Ongoing cabozantinib IP litigation with MSN Pharmaceuticals; second bench trial ruling expected spring 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":0.12,"consensus_revenue_estimate":null,"consensus_revenue_actual":425226000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12575294138.486397,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":255456,"accession_number":"0000939767-24-000040","cik":939767,"company_name":"EXELIXIS, INC.","ticker":"EXEL","form_type":"8-K","filed_at":"2024-03-29T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Jacqueline Wright not to stand for re-election at Exelixis 2024 annual meeting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jacqueline Wright will not stand for re-election to Exelixis board when her term expires at the 2024 annual meeting.","She will continue to serve as a director until the 2024 annual meeting.","She stated her decision was not due to any disagreement with the company regarding operations, policies, or practices."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":12575294138.486397,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":255455,"accession_number":"0000939767-24-000025","cik":939767,"company_name":"EXELIXIS, INC.","ticker":"EXEL","form_type":"8-K","filed_at":"2024-02-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Exelixis Q4 2023 revenue $479.7M, GAAP EPS $0.27, non-GAAP $0.33; FY revenue $1.83B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total Q4 revenues $479.7M (up from $423.9M YoY); cabozantinib net product revenues $429.3M.","GAAP diluted EPS $0.27 (Q4) and $0.65 (FY); non-GAAP diluted EPS $0.33 (Q4) and $0.90 (FY).","FY 2023 total revenues $1.83B, up 14% from $1.61B; net product revenues $1.63B.","R&D expenses $244.7M (Q4) vs $336.8M YoY; SG&A $131.4M vs $119.3M YoY.","Pipeline: regulatory strategies for cabozantinib label expansions; MSN IP litigation ruling expected spring 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":0.65,"consensus_revenue_estimate":null,"consensus_revenue_actual":1830208000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":12575294138.486397,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":255454,"accession_number":"0000939767-24-000002","cik":939767,"company_name":"EXELIXIS, INC.","ticker":"EXEL","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["2.02","2.05","5.02","8.01","9.01"],"status":"ready","headline":"Exelixis cuts 13% of workforce, authorizes $450M share repurchase, adds two directors","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Restructuring plan: workforce reduction of ~175 employees (13% of total headcount); total charges estimated at ~$25M, recognized in Q1 2024.","Board authorized $450M share repurchase program for 2024; company also issued preliminary FY2023 results and FY2024 guidance (details in press release).","Appointed Mary C. Beckerle and S. Gail Eckhardt to the Board, effective immediately; Alan M. Garber not standing for re-election."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12575294138.486397,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":272913,"accession_number":"0000939767-23-000127","cik":939767,"company_name":"EXELIXIS, INC.","ticker":"EXEL","form_type":"8-K","filed_at":"2023-12-20T23:59:59+00:00","items":["5.02","5.03","9.01"],"status":"ready","headline":"Exelixis amends severance plan and bylaws; updates change-in-control, advance notice rules","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["CEO severance period extended to 18 months for a Covered Termination outside Change in Control.","Participants now eligible for pro-rata annual bonus based on actual performance after non-CIC termination.","Bylaws updated for universal proxy rules; stockholder proposal deadline for 2024 annual meeting set to March 2, 2024.","Definition of Change in Control Termination revised to 3 months prior to 15 months after event.","Eliminated requirement to provide stockholder list at meetings; adjourned virtual meeting procedures clarified."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":12575294138.486397,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":272912,"accession_number":"0000939767-23-000112","cik":939767,"company_name":"EXELIXIS, INC.","ticker":"EXEL","form_type":"8-K","filed_at":"2023-11-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Exelixis Q3 revenue up 15% to $471.9M but GAAP net income drops to $1.0M from $73.2M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 total revenues $471.9M (up 14.6% YoY); net product rev $426.5M (up 16.4% YoY).","GAAP net income $1.0M ($0.00 EPS) vs $73.2M ($0.23 EPS) in Q3 2022; non-GAAP net income $32.1M ($0.10 EPS).","R&D expenses surged to $332.6M from $198.8M, driven by license/collaboration costs and pipeline investments.","Positive phase 3 data from CONTACT-02 (prostate) and CABINET (neuroendocrine tumors) studies for cabozantinib.","Appointed Dr. Amy Peterson as CMO in August; in-licensed XL309 (USP1 inhibitor) from Insilico Medicine."],"consensus_eps_estimate":null,"consensus_eps_actual":0.38,"consensus_revenue_estimate":null,"consensus_revenue_actual":1350556000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":12575294138.486397,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":289760,"accession_number":"0000939767-23-000109","cik":939767,"company_name":"EXELIXIS, INC.","ticker":"EXEL","form_type":"8-K","filed_at":"2023-09-19T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Exelixis finalizes separation with former CMO Vicki Goodman, consulting through Dec 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Goodman concluded service as EVP Product Development & CMO effective August 23, 2023.","Separation agreement provides severance payments and benefits under company's Change in Control and Severance Benefit Plan, payable in lump sum.","Consulting agreement for up to 4 months (Sept 1 to Dec 31, 2023) with monthly fee of $20,000.","Consulting may be terminated by either party with 5 business days' notice."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":12575294138.486397,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":289759,"accession_number":"0000939767-23-000093","cik":939767,"company_name":"EXELIXIS, INC.","ticker":"EXEL","form_type":"8-K","filed_at":"2023-08-23T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Exelixis CMO Vicki Goodman departs effective August 23, 2023; entitled to severance benefits","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Vicki L. Goodman, EVP Product Development & Medical Affairs and CMO, concludes service effective August 23, 2023.","Goodman is eligible for payments under Exelixis' Change in Control and Severance Benefit Plan.","No successor or interim CMO has been named in this filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":12575294138.486397,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":289758,"accession_number":"0000939767-23-000078","cik":939767,"company_name":"EXELIXIS, INC.","ticker":"EXEL","form_type":"8-K","filed_at":"2023-08-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Exelixis Q2 revenue $469.8M, GAAP EPS $0.25; CABOMETYX drives growth","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $469.8M (+12% YoY); net product revenues $409.6M (+18% YoY).","GAAP diluted EPS $0.25; non-GAAP diluted EPS $0.31, vs $0.22 and $0.28 last year.","CABOMETYX remains top TKI in RCC; growth driven by first-line combo with nivolumab.","Pipeline advances: zanzalintinib STELLAR-001 enrollment complete; XB002 dose selected.","Upcoming catalysts: CONTACT-02 readout, COSMIC-313 OS analysis, R&D Day Dec 12."],"consensus_eps_estimate":null,"consensus_eps_actual":0.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":878636000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12575294138.486397,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":289757,"accession_number":"0000939767-23-000072","cik":939767,"company_name":"EXELIXIS, INC.","ticker":"EXEL","form_type":"8-K","filed_at":"2023-07-24T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Exelixis settles patent litigation with Teva; generic CABOMETYX license begins Jan 1, 2031","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Settlement and License Agreement with Teva resolves patent litigation over generic CABOMETYX (cabozantinib).","Teva may market generic cabozantinib from January 1, 2031, if FDA approved and subject to standard conditions.","All pending Hatch-Waxman litigation between Exelixis and Teva in Delaware will be dismissed.","Agreement is confidential and subject to review by FTC and DOJ.","Expected to protect CABOMETYX exclusivity in the U.S. until at least January 1, 2031."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":12575294138.486397,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":310656,"accession_number":"0000939767-23-000069","cik":939767,"company_name":"EXELIXIS, INC.","ticker":"EXEL","form_type":"8-K","filed_at":"2023-06-05T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Exelixis annual meeting elects 11 directors, ratifies auditor, approves say-on-pay at 1-year frequency","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All 11 director nominees elected with strong support; Maria Freire received 226.9M for, 29.8M against.","Ratification of Ernst & Young as auditor: 249.6M for, 6.4M against, 0.9M abstain.","Advisory say-on-pay approved: 212.8M for, 42.8M against, 1.2M abstain.","Stockholders voted for annual say-on-pay frequency (250.8M for 1-year); board adopts annual frequency.","Dr. Lance Willsey resigned from board on May 7, 2023, and did not stand for re-election."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":12575294138.486397,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":310655,"accession_number":"0000939767-23-000047","cik":939767,"company_name":"EXELIXIS, INC.","ticker":"EXEL","form_type":"8-K","filed_at":"2023-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Exelixis Q1 revenue up 15% to $408.8M, but GAAP EPS falls to $0.12 on higher R&D spend","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $408.8M (+15% YoY); Cabozantinib franchise net product revenues $363.4M (+17% YoY).","GAAP net income $40.0M ($0.12 diluted EPS) vs $68.6M ($0.21) YoY; non-GAAP diluted EPS $0.16 vs $0.26.","R&D expense rose to $234.2M from $156.7M YoY, driven by license costs and pipeline manufacturing.","Announced $550M share repurchase program to be executed by end of 2023; reaffirms long-term confidence.","Pipeline advances: STELLAR-303 and -304 Phase 3 trials for zanzalintinib, XB002 Phase 1 dose escalation ongoing."],"consensus_eps_estimate":null,"consensus_eps_actual":0.12,"consensus_revenue_estimate":null,"consensus_revenue_actual":408788000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":12575294138.486397,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":310654,"accession_number":"0000950142-23-001374","cik":939767,"company_name":"EXELIXIS, INC.","ticker":"EXEL","form_type":"8-K","filed_at":"2023-05-08T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Exelixis director Lance Willsey resigns; Board adds Farallon nominee, ends proxy fight","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Lance Willsey, M.D. resigned from Exelixis board effective May 7, 2023; resignation relates to personal matter from over a decade ago.","Board will not contest Farallon's additional nominee David Johnson at May 31, 2023 Annual Meeting; recommends voting for its 10 remaining nominees.","Board previously nominated two Farallon candidates (Tomas Heyman, Robert Oliver) to replace two existing directors.","Board commits to replacing two additional directors over next two years (one per year) with new independent directors.","Over three years, five directors will have transitioned off, four new independent directors elected, including all Farallon nominees."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":12575294138.486397,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":310653,"accession_number":"0000950142-23-001077","cik":939767,"company_name":"EXELIXIS, INC.","ticker":"EXEL","form_type":"8-K","filed_at":"2023-04-13T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Exelixis board refresh: two directors not standing; new nominees after failed Farallon settlement","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Carl Feldbaum and Vincent Marchesi will not stand for re-election at 2023 Annual Meeting.","Board recommends Tomas Heyman and Robert Oliver as independent director nominees to fill the seats.","Farallon Capital Management demanded unprecedented access to confidential data; board refused settlement.","Annual Meeting date not yet set; board will be 11 directors with 10 independent after meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":12575294138.486397,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":329288,"accession_number":"0000939767-23-000035","cik":939767,"company_name":"EXELIXIS, INC.","ticker":"EXEL","form_type":"8-K","filed_at":"2023-03-22T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Exelixis files patent infringement suit against Cipla over generic CABOMETYX","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Filed complaint in Delaware district court against Cipla for ANDA seeking approval of generic cabozantinib tablets (20/40/60 mg).","Five patents asserted: U.S. Patents Nos. 8,877,776, 11,091,439, 11,091,440, 11,098,015, and 11,298,349, with latest expiry Feb. 10, 2032.","Exelixis seeks injunction and order delaying any FDA approval until after patent expirations; Cipla did not challenge compound patent expiring Aug. 14, 2026.","CABOMETYX is a key revenue driver for Exelixis; generic entry could impact sales if patents are invalidated or not infringed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12575294138.486397,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":329287,"accession_number":"0000939767-23-000033","cik":939767,"company_name":"EXELIXIS, INC.","ticker":"EXEL","form_type":"8-K","filed_at":"2023-03-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Exelixis authorizes $550M share repurchase program through end of 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board authorized up to $550M of common stock repurchases before end of 2023.","Program may be executed via open market, block trades, accelerated repurchase or exchanges.","Repurchases depend on capital needs, market conditions and alternative opportunities.","Program does not obligate Exelixis to repurchase any specific amount; may be suspended or discontinued."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":12575294138.486397,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":329286,"accession_number":"0000939767-23-000017","cik":939767,"company_name":"EXELIXIS, INC.","ticker":"EXEL","form_type":"8-K","filed_at":"2023-02-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Exelixis posts Q4 net loss $30.2M; cabozantinib franchise revenue $1.4B for FY2022","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 total revenues $423.9M, down 6% from $451.1M a year ago; cabozantinib U.S. net product revenues $377.4M.","GAAP diluted EPS $(0.09) for Q4 vs $0.29 in Q4 2021; full year GAAP diluted EPS $0.56 vs $0.72.","Non-GAAP diluted EPS $(0.03) for Q4 vs $0.35; full year non-GAAP diluted EPS $0.82 vs $1.01.","R&D expenses rose to $336.8M in Q4 (from $222.3M) on higher license and collaboration costs.","Company plans to initiate phase 3 studies of zanzalintinib and advance XB002 into full development in 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":0.56,"consensus_revenue_estimate":null,"consensus_revenue_actual":1611062000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":12575294138.486397,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":329285,"accession_number":"0000939767-23-000003","cik":939767,"company_name":"EXELIXIS, INC.","ticker":"EXEL","form_type":"8-K","filed_at":"2023-01-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Exelixis announces preliminary FY2022 results and FY2023 guidance; no specific figures in filing","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Press release contains preliminary unaudited financial results for Q4 and FY2022.","Company provided financial guidance for full year 2023.","Audit of FY2022 financials is ongoing; complete audited results expected Feb 7, 2023.","Preliminary results are subject to change upon completion of audit."],"consensus_eps_estimate":null,"consensus_eps_actual":0.56,"consensus_revenue_estimate":null,"consensus_revenue_actual":1611062000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":12575294138.486397,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":346902,"accession_number":"0000939767-22-000121","cik":939767,"company_name":"EXELIXIS, INC.","ticker":"EXEL","form_type":"8-K","filed_at":"2022-12-15T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Exelixis announces CSO transition; Peter Lamb steps down; Dana Aftab promoted","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Peter Lamb transitions from CSO to EVP, Scientific Strategy effective December 15, 2022.","Dana T. Aftab, Ph.D., appointed as new CSO and EVP, Discovery and Translational Research.","Dr. Aftab has over 24 years at Exelixis, most recently EVP, Business Operations.","He previously led discovery and development of cabozantinib and streamlined translational processes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":12575294138.486397,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":346901,"accession_number":"0000939767-22-000108","cik":939767,"company_name":"EXELIXIS, INC.","ticker":"EXEL","form_type":"8-K","filed_at":"2022-11-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Exelixis Q3 revenue $411.7M; cabozantinib franchise up 39% YoY; GAAP EPS $0.23","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $411.7M (up 25% YoY); cabozantinib net product revenue $366.5M (+39% YoY).","GAAP net income $73.2M ($0.23 diluted EPS) vs $38.2M ($0.12) prior year; non-GAAP EPS $0.31.","Announced option deals with Cybrexa and Sairopa to access early-stage oncology assets.","Cash and investments $2.1B at quarter end, up from $1.9B at Dec 2021.","R&D expenses $198.8M (up from $163.4M); SG&A $115.0M (up from $101.6M)."],"consensus_eps_estimate":null,"consensus_eps_actual":0.65,"consensus_revenue_estimate":null,"consensus_revenue_actual":1187145000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":12575294138.486397,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":363280,"accession_number":"0000939767-22-000101","cik":939767,"company_name":"EXELIXIS, INC.","ticker":"EXEL","form_type":"8-K","filed_at":"2022-09-02T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Exelixis files second patent infringement suit against Teva over generic CABOMETYX","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Exelixis filed complaint against Teva for infringing U.S. Patent No. 11,298,349 covering CABOMETYX (cabozantinib) tablets.","Teva filed ANDA with Paragraph IV certification; Exelixis seeks injunction and FDA approval delay until patent expires Feb 10, 2032.","This is the second case; first case (2021) is stayed administratively, asserting three other patents expiring July 9, 2033.","No trial scheduled yet; Exelixis seeks equitable relief to block Teva's generic launch before patent expiration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":12575294138.486397,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":363279,"accession_number":"0000939767-22-000096","cik":939767,"company_name":"EXELIXIS, INC.","ticker":"EXEL","form_type":"8-K","filed_at":"2022-08-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Exelixis Q2 2022 revenue $419.4M, cabozantinib net product revenue $347M, GAAP EPS $0.22","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $419.4M, up from $385.2M in Q2 2021; cabozantinib franchise net product revenue $347.0M, up 22% YoY.","GAAP net income $70.7M ($0.22 diluted EPS) vs $96.1M ($0.30) in Q2 2021; non-GAAP EPS $0.28.","Cash and investments $2.0B at June 30, 2022, up from $1.9B at year-end 2021.","Positive PFS data for COSMIC-313; initiated STELLAR-303 phase 3 for XL092 and phase 1 for XL114.","Signed business development agreements with BioInvent and Ryvu Therapeutics to expand biologics capabilities."],"consensus_eps_estimate":null,"consensus_eps_actual":0.43,"consensus_revenue_estimate":null,"consensus_revenue_actual":775407000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":12575294138.486397,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":363278,"accession_number":"0000939767-22-000083","cik":939767,"company_name":"EXELIXIS, INC.","ticker":"EXEL","form_type":"8-K","filed_at":"2022-07-19T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Exelixis sues MSN for generic CABOMETYX, asserting new patent expiring 2032","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Filed patent infringement suit against MSN for generic CABOMETYX, asserting U.S. Patent No. 11,298,349 (expires Feb 10, 2032).","This is the fourth case; prior cases involve patents expiring Oct 8, 2030 and Jan 15, 2030, with trials in May 2022 (pending) and May 2023.","Exelixis seeks injunction to block FDA approval of MSN's ANDA until expiration of the asserted patents.","No trial date set for this new case; litigation ongoing in Delaware District Court."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":12575294138.486397,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":383049,"accession_number":"0000939767-22-000070","cik":939767,"company_name":"EXELIXIS, INC.","ticker":"EXEL","form_type":"8-K","filed_at":"2022-05-27T23:59:59+00:00","items":["5.02","5.07"],"status":"ready","headline":"Exelixis shareholders approve 28.5M share increase to 2017 Equity Plan at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved amendment to 2017 Equity Incentive Plan, adding 28.5M shares and adjusting fungible share counting multiplier to 2.","All 11 director nominees elected (e.g., Feldbaum, Freire, Garber) with majority support; no departures.","Ratified Ernst & Young as independent auditor for FY2022 (276M for, 4M against).","Advisory say-on-pay resolution approved with 243.6M for vs 6.3M against (excluding broker non-votes)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":12575294138.486397,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":383048,"accession_number":"0000939767-22-000057","cik":939767,"company_name":"EXELIXIS, INC.","ticker":"EXEL","form_type":"8-K","filed_at":"2022-05-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Exelixis Q1 2022 revenue $356M, EPS $0.21; cabozantinib franchise $310.3M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $356.0M vs $270.2M YoY; net product revenues $310.3M vs $227.2M, driven by higher cabozantinib volume.","GAAP net income $68.6M ($0.21 diluted EPS) vs $1.6M ($0.00); non-GAAP EPS $0.26 vs $0.09.","Cabozantinib franchise growth: increased demand for CABOMETYX+OPDIVO in first-line RCC and DTC label expansion.","Cash and investments $2.0B at March 31, 2022, up from $1.9B at December 31, 2021.","Pipeline advancing: XL092 phase 3 STELLAR-303 to initiate Q2 2022; phase 1 trials of XL092, XB002, XL102 ongoing."],"consensus_eps_estimate":null,"consensus_eps_actual":0.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":355980000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12575294138.486397,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":383047,"accession_number":"0000939767-22-000046","cik":939767,"company_name":"EXELIXIS, INC.","ticker":"EXEL","form_type":"8-K","filed_at":"2022-04-13T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Exelixis director Charles Cohen to not stand for re-election at 2022 annual meeting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Charles Cohen, Ph.D. notified Exelixis on April 11, 2022 of his decision not to stand for re-election.","Resignation effective as of the 2022 annual meeting of stockholders.","Cohen indicated his decision was not due to any disagreement with Exelixis' operations, policies, or practices."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":12575294138.486397,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":400875,"accession_number":"0000939767-22-000029","cik":939767,"company_name":"EXELIXIS, INC.","ticker":"EXEL","form_type":"8-K","filed_at":"2022-02-23T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Exelixis files new patent infringement suit against MSN over generic CABOMETYX","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Filed complaint in Delaware asserting infringement of three new patents (11,091,439; 11,091,440; 11,098,015) related to cabozantinib.","MSN amended its ANDA for generic CABOMETYX tablets (20/40/60 mg); Exelixis seeks injunction and approval date no earlier than patent expiration (latest Jan 15, 2030).","This new case is separate from the 2019/2020 MSN ANDA Actions, which are scheduled for trial in May 2022.","Exelixis also seeks order that FDA approval of MSN's ANDA be delayed until after patent expirations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12575294138.486397,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-02-23T23:59:59+00:00|400875"}